Scheubeck, Gabriel http://orcid.org/0009-0004-2546-6154
Jiang, Linmiao http://orcid.org/0000-0002-9009-4236
Hermine, Olivier
Kluin-Nelemans, Hanneke C.
Schmidt, Christian
Unterhalt, Michael
Rosenwald, Andreas
Klapper, Wolfram http://orcid.org/0000-0001-7208-4117
Evangelista, Andrea
Ladetto, Marco
Jerkeman, Mats http://orcid.org/0000-0003-4509-6707
Ferrero, Simone http://orcid.org/0000-0002-9711-1502
Dreyling, Martin
Hoster, Eva http://orcid.org/0000-0002-0749-1389
Funding for this research was provided by:
AbbVie
AstraZeneca
Bristol-Myers Squibb
Gilead Sciences
Les Laboratories Pierre Fabre
Janssen Biotech
Roche
Novartis | Sandoz
Bayer
Amgen
Article History
Received: 5 March 2023
Revised: 28 June 2023
Accepted: 17 July 2023
First Online: 26 July 2023
Competing interests
: GS, LJ, OH, HCK-N, CS, MU, AR, WK, ML, AE and EH: None. MJ—Honoraria: Abbvie, Astra Zeneca, BMS, Genmab, Gilead, Pierre Fabre, Janssen, Roche. Research support: Abbvie, Astra Zeneca, BMS, Gilead, Janssen, Roche. SF—Research funding: Janssen, Morphosys, Gilead, Beigene. Consultancy: EusaPharma, Janssen, Sandoz, Abbvie. Advisory Board: EusaPharma, Janssen, Clinigen, Incyte, Italfarmaco. Speakers Honoraria: Janssen, EusaPharma, Servier, Gentili. MD—Research Support (institution): Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche. <b>-</b> Employee: -Major Stockholder: -Speakers Bureau: -Speakers Honoraria: Amgen, Astra Zeneca, Gilead/Kite, Janssen, Lilly, Novartis, Roche. <b>-</b> Scientific Advisory Board: Astra Zeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis, Roche.